A Phase 3, Multicenter, Open-label Extension Study To Assess The Safety And Efficacy Of Certolizumab Pegol As Additional Medication To Methotrexate In Chinese Subjects With Active Rheumatoid Arthritis Who Participated In RA0044.
Phase of Trial: Phase III
Latest Information Update: 20 Jan 2017
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms RAPID-C OLE
- Sponsors UCB Pharma SA
- 07 Jun 2017 Biomarkers information updated
- 16 Jan 2017 Status changed from active, no longer recruiting to completed.
- 03 Jun 2016 Status changed from recruiting to active, no longer recruiting.